Department of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska 2, SI-1000 Ljubljana, Slovenia.
Curr Gene Ther. 2010 Aug;10(4):300-11. doi: 10.2174/156652310791823425.
Electrogene therapy combines administration of plasmid DNA into tissue followed by local application of electric pulses. In electrogene therapy with interleukin-12 (IL-12), different routes of administration, different doses of plasmid DNA and different protocols for delivery of electric pulses were evaluated in numerous preclinical studies. Antitumor effectiveness was tested in different types of primary tumors, distantly growing tumors and induced metastases. Intratumoral IL-12 electrogene therapy has been proved to be very effective in local tumor control, having also a systemic effect. Intramuscular and peritumoral IL-12 electrogene therapy had also a pronounced systemic effect and when combined with other treatment strategies resulted in tumor cures. Antitumor effectiveness of IL-12 electrogene therapy is due to the induction of adaptive immunity and innate resistance and anti-angiogenic action. Translation of preclinical studies into clinical trials in human and veterinary oncology has started with encouraging results that would hopefully lead to further investigation of this therapy, also in combination with other cancer treatment modalities.
电基因治疗将质粒 DNA 递送至组织中，随后局部应用电脉冲。在白细胞介素 12（IL-12）的电基因治疗中，在众多临床前研究中评估了不同的给药途径、不同剂量的质粒 DNA 和不同的电脉冲传递方案。在不同类型的原发性肿瘤、远处生长的肿瘤和诱导转移中测试了抗肿瘤的有效性。瘤内 IL-12 电基因治疗已被证明在局部肿瘤控制方面非常有效，同时也具有全身作用。肌肉内和肿瘤周围的 IL-12 电基因治疗也具有明显的全身作用，并且与其他治疗策略结合使用时可治愈肿瘤。IL-12 电基因治疗的抗肿瘤作用是由于诱导适应性免疫和先天抵抗以及抗血管生成作用。从临床前研究到人类和兽医肿瘤学的临床试验的转化已经开始，结果令人鼓舞，希望这将促使对这种治疗方法进行进一步研究，也与其他癌症治疗方式结合进行研究。
